Icon

ZONTIVITY (nda204886)- (EQ 2.08MG BASE)

VORAPAXAR SULFATE KEY THERAP
EQ 2.08MG BASE
No No
2027-Dec-23 2019-May-08
None None
None No
ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 2.08MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.